Laparoscopic Sleeve Gasterectomy With or Without Pyloric Botulinum Neurotoxin Injection
Primary Purpose
Morbid Obesity
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
laparoscopic sleeve gastrectomy
Sponsored by
About this trial
This is an interventional treatment trial for Morbid Obesity
Eligibility Criteria
Inclusion Criteria:
Body mass index >40 or >35 with hypertension or DM
Exclusion Criteria:
Previous bariatric surgery
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
LSG
BTX-LSG
Arm Description
patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
Outcomes
Primary Outcome Measures
number pf patients developing postoperative gastric leakage
Secondary Outcome Measures
percent of patients with excess weight loss
Full Information
NCT ID
NCT02325141
First Posted
December 19, 2014
Last Updated
December 19, 2014
Sponsor
Mansoura University
1. Study Identification
Unique Protocol Identification Number
NCT02325141
Brief Title
Laparoscopic Sleeve Gasterectomy With or Without Pyloric Botulinum Neurotoxin Injection
Official Title
Laparoscopic Sleeve Gasterectomy With or Without Pyloric Sphincter Botulinum Neurotoxin Injection: a Comparative Study
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mansoura University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Leakage is the most common complication after laparoscopic sleeve gastrectomy which may amount to 20% in some studies. We hypothesize that Clostridium botulinum neurotoxin A (BTX-A) injection into the pyloric sphincter during the operation may decrease the risk of postoperative gastric leakage.
Detailed Description
Laparoscopic sleeve gastrectomy (LSG) provides similar weight loss and resolution of obesity comorbidities to that of duodenal switch and Roux-en-Y gastric bypass. Inspite of its encouraging results, the pretended feasibility of the operative procedure can be associated with a remarkable operative morbidity. The main reason is gastric leakage from stable line which occurs in about 0-20% of the cases. The main accepted cause of leakage is formation of a high gastric tube pressure. Injection of BTX-A into the pyloric sphincter intraoperative will cause temporal paralysis of pyloric sphincter muscles postoperatively; so the pressure inside the gastric pouch will be decreased abolishing the formation of high pressure tube with subsequent leakage.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
130 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LSG
Arm Type
Active Comparator
Arm Description
patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
Arm Title
BTX-LSG
Arm Type
Active Comparator
Arm Description
patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
Intervention Type
Procedure
Intervention Name(s)
laparoscopic sleeve gastrectomy
Intervention Description
creation of a gastric tube of 100cc using a stapler.
Primary Outcome Measure Information:
Title
number pf patients developing postoperative gastric leakage
Time Frame
0ne year
Secondary Outcome Measure Information:
Title
percent of patients with excess weight loss
Time Frame
one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Body mass index >40 or >35 with hypertension or DM
Exclusion Criteria:
Previous bariatric surgery
12. IPD Sharing Statement
Learn more about this trial
Laparoscopic Sleeve Gasterectomy With or Without Pyloric Botulinum Neurotoxin Injection
We'll reach out to this number within 24 hrs